224775-01-3

Upstream product

• 352-11-4 1-chloromethyl-4-fluorobenzene 
• 14001-66-2 5-bromo-2-methoxypyrimidine 
• 224776-37-8 2-(ethoxymethylene)-3-(2-methoxypyrimidin-5-yl)propionic acid ethyl ester 
• 304693-85-4 (Z)-3-Hydroxy-2-(2-methoxy-pyrimidin-5-ylmethyl)-acrylic acid ethyl ester 
• 224776-36-7 ethyl 3-(2-methoxypyrimidin-5-yl)propionate 
• 224776-35-6 ethyl 3-(2-methoxypyrimidin-5-yl)acrylate 

Downstream Products

• 259532-11-1 (5-{2-(4-fluoro-benzylsulfanyl)-1-[(methyl-octyl-carbamoyl)-methyl]-4-oxo-1,4-dihydro-pyrimidin-5-ylmethyl}-2-oxo-2H-pyrimidin-1-yl)-acetic acid ethyl ester 
• 259532-12-2 (5-{2-(4-fluoro-benzylsulfanyl)-1-[(methyl-octyl-carbamoyl)-methyl]-4-oxo-1,4-dihydro-pyrimidin-5-ylmethyl}-2-oxo-2H-pyrimidin-1-yl)-acetic acid 
• 224775-05-7 1-(N-Methyl-N-(oct-1-yl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(2-oxopyrimid-5-ylmethyl)pyrimidin-4-one 

Relevant academic research and scientific papers

The identification of a potent, water soluble inhibitor of lipoprotein-associated phospholipase A2

Modification of the pyrimidone 5-substituent in a series of 1-((amidolinked)-alkyl)-pyrimidones, lipophilic inhibitors of lipoprotein-associated phospholipase A2, has given inhibitors of nanomolar potency and improved physicochemical properties

Pyrimidinone compounds and pharmaceutical compositions containing them

A group of novel pyrimidone compounds are inhibitors of the enzyme LDL PLA2and therefore of use in treating atherosclerosis.